arrow_back Trending Legislation
Share share

Ending Tax Deductions for Direct-to-Consumer Prescription Drug Ads.

This bill eliminates the ability for pharmaceutical companies to deduct the cost of direct-to-consumer prescription drug advertising from their taxable income. This change aims to increase tax revenue from drug manufacturers and potentially reduce the volume of drug advertisements seen by the public across all media platforms. The law does not directly affect drug prices or access for citizens.
Key points
Pharmaceutical companies will no longer receive tax breaks for expenses related to advertising prescription drugs directly to the general public.
The ban on deductions covers all advertising formats, including TV, radio, print, billboards, and digital platforms like social media.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
No Tax Breaks for Drug Ads Act
Print number: S 4691
Sponsor: Sen. Shaheen, Jeanne [D-NH]
Process start date: 2024-07-11
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Ending Tax Deductions for Direct-to-Consumer Prescription Drug Ads.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 4691.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-07-11.

What are the main provisions?

Key points include:

  • Pharmaceutical companies will no longer receive tax breaks for expenses related to advertising prescription drugs directly to the general public.
  • The ban on deductions covers all advertising formats, including TV, radio, print, billboards, and digital platforms like social media.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Shaheen, Jeanne [D-NH].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Analysis and Potential Impact of S 4691

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Taxes Health